Responses
Regular and young investigator award abstracts
Clinical trials completed
291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
